{"url":"https://whatshealthyandwhy.com/butterbur/migraine-and-allergy-relief","path":"/butterbur/migraine-and-allergy-relief","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/butterbur/migraine-and-allergy-relief.json","markdown":"https://whatshealthyandwhy.com/butterbur/migraine-and-allergy-relief.md"},"topic":{"slug":"butterbur","name":"Butterbur","url":"https://whatshealthyandwhy.com/butterbur"},"slug":"migraine-and-allergy-relief","order":1,"title":"Migraine Prevention and Allergic Rhinitis","question":"Does butterbur prevent migraines and relieve seasonal allergies?","answer":"Butterbur extract certified free of liver-toxic pyrrolizidine alkaloids probably cuts migraine frequency and eases seasonal allergies about as well as antihistamines.","description":"How butterbur (Petasites hybridus) reduces migraine frequency and allergy symptoms through CGRP inhibition, leukotriene suppression, and anti-inflammatory petasins — with critical safety notes on PA-free extracts","confidence":4,"confidenceNote":"Four RCTs (245 migraine patients; 131 to 330 per allergy trial) agree and the AAN rates it Level A, but trials are short.","evidenceSummary":{"rctCount":4,"observationalCount":0,"metaAnalysisCount":1,"totalParticipants":"890+","replicated":true,"newestStudyYear":2022},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["For migraine prevention, studies used 75 mg of a standardized PA-free extract twice daily; allow 2–3 months to judge [1].","Buy only products certified PA-free (below 0.1 ppm, per the certificate of analysis); never use raw butterbur powder or tea.","For seasonal allergies, a Ze339 extract was tested for 2 weeks, with relief typically within 1–2 weeks [2][4]."],"cautions":["Raw or uncertified butterbur contains liver-damaging pyrrolizidine alkaloids; stop and check liver enzymes if jaundice, dark urine or fatigue develop [6].","Not for use in pregnancy; it may interact with CYP3A4-metabolized medications, so ask a pharmacist or physician.","It is a daily preventive, not a treatment for a migraine already under way; long-term safety beyond 16 weeks is limited."],"simpleText":"Butterbur is a marshy European plant whose root extract has earned rare recognition in mainstream neurology: the American Academy of Neurology classifies it at Level A — the highest evidence tier — for preventing episodic migraines [5]. A landmark randomized trial found that 75 mg twice daily reduced migraine attack frequency by 48% compared to 26% for placebo over four months [1]. For seasonal allergies, separate trials found butterbur comparable to the antihistamine cetirizine, without sedation [2]. One critical safety rule applies to any butterbur product: it must be certified free of pyrrolizidine alkaloids (PAs), compounds found in raw butterbur that can damage the liver. Only certified PA-free extracts should ever be used — raw or unprocessed butterbur is not safe for internal consumption.","mediumText":"How Butterbur Works\n\nButterbur root contains two key active compounds, petasin and isopetasin, which drive its effects through mechanisms distinct from most herbal anti-inflammatories [6].\n\nBlocking CGRP release: Calcitonin gene-related peptide (CGRP) is the central signaling molecule in migraine — it is released by trigeminal nerve fibers, causes vasodilation of meningeal arteries, and amplifies pain transmission in the trigeminovascular system. Butterbur petasins inhibit CGRP release from meningeal afferents during the processes that trigger a migraine, dampening the cascade before it escalates. This is the same target as the newest class of migraine medications (CGRP monoclonal antibodies and gepants), making butterbur mechanistically aligned with modern pharmacotherapy [6].\n\nInhibiting leukotrienes and prostaglandins: Petasins suppress the enzyme 5-lipoxygenase, which produces leukotrienes — potent inflammatory mediators that trigger bronchoconstriction and mucus secretion in allergic reactions, and contribute to neurogenic inflammation in migraine. Butterbur also inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis. This dual lipoxygenase-cyclooxygenase inhibition is particularly relevant to allergic rhinitis: leukotrienes are the primary drivers of nasal congestion that antihistamines cannot fully address [6].\n\nDesensitizing pain receptors: Petasins act on TRPA1 and TRPV1 ion channels — pain and temperature sensors widely expressed in trigeminal neurons. Modulating these channels reduces nociceptive signaling in the nerve pathways responsible for migraine pain [6].\n\nPractical Use for Migraines\n\nButterbur is a preventive treatment taken daily, not an acute remedy for a migraine in progress. It will not abort a migraine once it has started.\n\nDosage: The clinically studied dose for migraine prevention is 75 mg of a standardized PA-free extract twice daily (150 mg total per day). The 50 mg twice-daily dose showed a trend toward reduction but did not reach statistical significance in the main trial [1]. At least 2–3 months of consistent use is needed before assessing whether it is working.\n\nProduct selection: Only use products certified PA-free (pyrrolizidine alkaloid-free). Petadolex is the specific extract used in clinical trials and has the most documented safety data. Do not use unprocessed butterbur powder or teas, and be cautious with products from manufacturers who do not publish PA testing results.\n\nWho might benefit most: People with frequent episodic migraine (2–6 attacks per month) showed the most robust effects in trials. Those with fewer than 2 attacks per month may see less measurable benefit, as migraine variability makes it difficult to detect a treatment effect against natural fluctuation.\n\nPractical Use for Allergies\n\nFor seasonal allergic rhinitis, Ze339 butterbur extract has been studied at 8 mg three times daily (total 24 mg/day of the standardized extract). This dose performed comparably to cetirizine 10 mg and fexofenadine 180 mg in reducing nasal and eye symptoms, with the advantage of no drowsiness — a significant benefit for people who need to drive, operate machinery, or maintain mental focus [2][4].\n\nOnset for allergies: Symptom relief typically begins within 1–2 weeks of consistent use.\n\nWhen to use: Most useful for intermittent or seasonal allergic rhinitis. For perennial (year-round) allergies or severe asthma, evidence is more limited and medical oversight is appropriate.\n\nSafety: The Pyrrolizidine Alkaloid Warning\n\nThis is the most important thing to understand about butterbur. The raw plant contains unsaturated pyrrolizidine alkaloids (PAs) — compounds that accumulate in the liver, cause veno-occlusive disease, and are classified as probable human carcinogens at sufficient doses. Several commercial butterbur products sold online have tested positive for PA contamination, and hepatotoxicity cases linked to contaminated products have been reported.\n\nCertified PA-free extracts do not carry this risk. Products like Petadolex (used in the clinical trials) use solvent extraction processes that remove PAs to below detectable limits. When certified PA-free products are used at studied doses for up to 16 weeks, including studies in children and adolescents, no liver enzyme elevations or hepatotoxicity have been reported [6].\n\nPractical rule: Before purchasing, verify the product's certificate of analysis confirms PAs are below 0.1 ppm. If this information is not available from the manufacturer, choose a different product.\n\nOther precautions: Not for use during pregnancy. May interact with CYP3A4-metabolized medications (consult a pharmacist or physician). Discontinue and check liver enzymes if jaundice, dark urine, or fatigue develop during use.\n\nFor related approaches to managing migraines naturally, see our feverfew page and our magnesium page.","deepText":"Evidence Review\n\nThe Key Migraine RCT: Lipton et al. (2004)\n\nThe pivotal trial establishing butterbur as a Level A migraine preventive was a three-arm, parallel-group, randomized controlled trial conducted by Lipton and colleagues at multiple centers [1]. 245 patients meeting International Headache Society migraine criteria, aged 18–65 with 2–6 attacks per month over the preceding three months, were randomized to Petasites extract 75 mg twice daily, 50 mg twice daily, or matching placebo for four months.\n\nThe per-protocol analysis (n = 202) found:\n\n- 75 mg twice-daily group: migraine attack frequency reduced by 48% (p = 0.0012 vs. placebo)\n- 50 mg twice-daily group: 36% reduction (p = 0.127 vs. placebo — a trend but not statistically significant)\n- Placebo group: 26% reduction (the typical placebo response in migraine trials)\n\nThe absolute superiority of the 75 mg dose over placebo was 22 percentage points, representing roughly one fewer migraine per month in a patient averaging 3–4 attacks per month at baseline. Responder rates — the proportion of patients achieving at least 50% reduction in attack frequency — were 68% with 75 mg, 56% with 50 mg, and 49% with placebo. The most common adverse events were burping (9.3% with butterbur vs. 3.7% with placebo) and nausea; no serious adverse events were attributed to the study drug.\n\nThis study used Petadolex, a PA-free standardized extract. It was classified as a Class I (highest quality) trial in the American Academy of Neurology evidence review and contributed to the Level A designation for butterbur in their 2012 guideline update.\n\nAAN/AHS Level A Recommendation: Holland et al. (2012)\n\nThe American Academy of Neurology and American Headache Society jointly published an evidence-based guideline update reviewing complementary treatments for episodic migraine prevention [5]. After systematic review of the clinical trial evidence using their quality standards classification system, butterbur was the only natural product to receive a Level A recommendation — the same evidence tier as established pharmaceutical preventives such as topiramate, valproate, and propranolol.\n\nThe guideline stated that Petasites hybridus should be \"offered to patients with migraine to reduce the frequency and severity of migraine attacks\" (Level A, Class I evidence). This classification requires at least two high-quality, independently conducted RCTs showing efficacy — a standard that butterbur met through the Lipton 2004 trial and an earlier confirming study.\n\nNo other herbal treatment for migraine prevention meets this evidentiary bar. Feverfew, by comparison, received a Level B recommendation in the same guideline — one level below butterbur. Magnesium and riboflavin also received Level B recommendations.\n\nSeasonal Allergic Rhinitis: Schapowal Trials (2002–2005)\n\nButterbur vs. cetirizine (2002): Schapowal and the Petasites Study Group conducted a randomized double-blind parallel group trial in 131 patients with seasonal allergic rhinitis, comparing Ze339 butterbur extract (one tablet four times daily) to cetirizine 10 mg once daily for two weeks [2]. Primary outcome was physician- and patient-rated overall symptom improvement on a validated scale.\n\nButterbur and cetirizine produced equivalent overall improvements in allergic symptom scores. Critically, patient-reported symptoms of drowsiness were significantly higher in the cetirizine group — a meaningful finding since first-generation antihistamine sedation is a primary reason patients discontinue allergy treatment. No serious adverse events were reported in either group. The equivalence to cetirizine without sedation established butterbur as a clinically relevant non-sedating option.\n\nDose-response study (2004): In a subsequent double-blind RCT in 186 patients randomized to Ze339 high-dose, low-dose, or placebo, both active doses significantly outperformed placebo on total nasal symptom scores, confirming dose-related efficacy and ruling out a non-specific effect [3].\n\nVs. fexofenadine (2005): A larger trial of 330 patients compared Ze339 to fexofenadine 180 mg and placebo over 2 weeks. Response rates by day 14 were 32% (butterbur) vs. 33% (fexofenadine) vs. 5% (placebo) [4]. No serious adverse events occurred in the butterbur group and no clinically significant changes in liver enzymes (ALT, AST, GGT) were observed — important safety confirmation at therapeutic doses.\n\nTaken together, these three well-conducted trials provide consistent evidence that PA-free butterbur extract reduces allergic rhinitis symptoms comparably to second-generation antihistamines without inducing sedation. A 2007 systematic review of herbal medicines for allergic rhinitis found six randomized trials of butterbur extract and concluded that the evidence is encouraging: butterbur appeared superior to placebo or similarly effective to non-sedating antihistamines for intermittent allergic rhinitis. The reviewers cautioned that independent replication is needed, because the manufacturer financed the three large trials [7].\n\nMechanism: 2022 Review by Borlak et al.\n\nThe most recent comprehensive review of butterbur's mechanism of action synthesized data from molecular pharmacology, receptor binding studies, and translational research [6]. The authors identified petasin and isopetasin as the therapeutically active compounds responsible for butterbur's effects in both migraine and allergies, with the following key findings: …","deepTruncated":true,"references":[{"id":"1","title":"Petasites hybridus root (butterbur) is an effective preventive treatment for migraine","authors":"Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A","year":2004,"journal":"Neurology","pmid":"15623680","url":"https://pubmed.ncbi.nlm.nih.gov/15623680/"},{"id":"2","title":"Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis","authors":"Schapowal A; Petasites Study Group","year":2002,"journal":"BMJ","pmid":"11799030","url":"https://pubmed.ncbi.nlm.nih.gov/11799030/"},{"id":"3","title":"Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study","authors":"Schapowal A; Study Group","year":2004,"journal":"Archives of Otolaryngology-Head and Neck Surgery","pmid":"15611396","url":"https://pubmed.ncbi.nlm.nih.gov/15611396/"},{"id":"4","title":"Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339","authors":"Schapowal A; Study Group","year":2005,"journal":"Phytotherapy Research","pmid":"16114089","url":"https://pubmed.ncbi.nlm.nih.gov/16114089/"},{"id":"5","title":"Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults","authors":"Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E","year":2012,"journal":"Neurology","pmid":"22529203","url":"https://pubmed.ncbi.nlm.nih.gov/22529203/"},{"id":"6","title":"Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review","authors":"Borlak J, Diener HC, Kleeberg-Hartmann J, Messlinger K, Silberstein S","year":2022,"journal":"Frontiers in Neurology","pmid":"35585841","url":"https://pubmed.ncbi.nlm.nih.gov/35585841/"},{"id":"7","title":"Herbal medicines for the treatment of allergic rhinitis: a systematic review","authors":"Guo R, Pittler MH, Ernst E","year":2007,"journal":"Annals of Allergy, Asthma & Immunology","pmid":"18219828","url":"https://pubmed.ncbi.nlm.nih.gov/18219828/"}],"wordCount":1845,"source":{"path":"src/content/topics/butterbur/migraine-and-allergy-relief.md"},"citeAs":"“Does butterbur prevent migraines and relieve seasonal allergies?.” What's Healthy and Why. https://whatshealthyandwhy.com/butterbur/migraine-and-allergy-relief","notice":"General information backed by peer-reviewed research, not medical advice."}